Selected Grantee Publications
- 644 results found
Establishment of a Practical Sperm Cryopreservation Pathway for the Axolotl (Ambystoma mexicanum): A Community-Level Approach to Germplasm Repository Development
Coxe et al., Animals (Basel). 2024.
https://pubmed.ncbi.nlm.nih.gov/38254376/
The axolotl (Ambystoma mexicanum) is an important biomedical research model for organ regeneration, but housing and maintaining live animals is expensive and risky as new transgenic lines are developed. The authors report an initial practical pathway for sperm cryopreservation to support germplasm repository development. They assembled a pathway through the investigation of axolotl sperm collection by stripping, refrigerated storage in various osmotic pressures, cryopreservation in various cryoprotectants, and in vitro fertilization using thawed sperm. This work is the first report of successful production of axolotl offspring with cryopreserved sperm and provides a general framework for pathway development to establish Ambystoma germplasm repositories for future research and applications. Supported by ORIP (R24OD010441, R24OD028443, P40OD019794).
The Gene Expression Profile and Cell of Origin of Canine Peripheral T-Cell Lymphoma
Owens et al., BMC Cancer. 2024.
https://pubmed.ncbi.nlm.nih.gov/38166662/
Peripheral T-cell lymphoma (PTCL) refers to a heterogenous group of T-cell neoplasms with poor treatment responses and survival times. Canine PTCL clinically and immunophenotypically resembles the most common human subtype, PTCL-NOS (PTCL-not otherwise specified), and is a naturally occurring model for human PTCL. Gene expression profiling in human PTCL-NOS has helped characterize this ambiguous diagnosis into distinct subtypes, but similar gene expression profiling in canine PTCL is lacking. Canine CD4+ PTCL most closely resembles the GATA3-PTCL subtype of PTCL-NOS and may originate from an earlier stage of T-cell development than the more conventionally posited mature T-helper cell origin. Supported by ORIP (T32OD010437).
Newly Identified Roles for PIEZO1 Mechanosensor in Controlling Normal Megakaryocyte Development and in Primary Myelofibrosis
Abbonante et al., American Journal of Hematology. 2024.
https://pubmed.ncbi.nlm.nih.gov/38165047/
Mechanisms through which mature megakaryocytes (Mks) and their progenitors sense the bone marrow extracellular matrix to promote lineage differentiation are only partially understood. The authors report that PIEZO1, a mechanosensitive cation channel, is expressed in mouse and human Mks, and activation of PIEZO1 increased the number of immature Mks in mice. Piezo1/2 knockout mice show an increase in Mk size and platelet count, both at basal state and upon marrow regeneration. Together, these data suggest that PIEZO1 places a brake on Mk maturation and platelet formation in physiology, and its upregulation might contribute to aggravating disease. Supported by ORIP (K01OD025290), NHGRI, NHLBI, and NCATS.
Conduction-Dominated Cryomesh for Organism Vitrification
Guo et al., Advanced Science. 2024.
https://pubmed.ncbi.nlm.nih.gov/38018294/
Vitrification-based cryopreservation via cryomesh is a promising approach for maintaining biodiversity, health care, and sustainable food production via long-term preservation of biological systems. Here, researchers conducted a series of experiments aimed at optimizing the cooling and rewarming rates of cryomesh to increase the viability of various cryopreserved biosystems. They found that vitrification was significantly improved by increasing thermal conductivity, reducing mesh wire diameter and pore size, and minimizing the nitrogen vapor barrier of the conduction-dominated cryomesh. Cooling rates increased twofold to tenfold in a variety of biosystems. The conduction-dominated cryomesh improved the cryopreservation outcomes of coral larvae, Drosophila embryos, and zebrafish embryos by vitrification. These findings suggest that the conduction-dominated cryomesh can improve vitrification in such biosystems for biorepositories, agriculture and aquaculture, and research. Supported by ORIP (R24OD028444, R21OD028758, R24OD034063, R21OD028214), NIDDK, and NIGMS.
The Monarch Initiative in 2024: An Analytic Platform Integrating Phenotypes, Genes and Diseases Across Species
Putman et al., Nucleic Acids Research. 2024.
https://pubmed.ncbi.nlm.nih.gov/38000386/
The Monarch Initiative aims to bridge the gap between the genetic variations, environmental determinants, and phenotypic outcomes critical for translational research. The Monarch app provides researchers access to curated data sets with information on genes, phenotypes, and diseases across species and advanced analysis tools for such diverse applications as variant prioritization, deep phenotyping, and patient profile matching. Researchers describe upgrades to the app, including scalable cloud-based infrastructure, simplified data ingestion and knowledge graph integration systems, enhanced data mapping and integration standards, and a new user interface with novel search and graph navigation features. A customized plugin for OpenAI’s ChatGPT allows the use of large language models to interrogate knowledge in the Monarch graph and increase the reliability of the responses of Monarch’s analytic tools. These upgrades will enhance clinical diagnosis and the understanding of disease mechanisms. Supported by ORIP (R24OD011883), NLM, and NHGRI.
Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population
Cruz Cisneros et al., Vaccines. 2024.
https://pubmed.ncbi.nlm.nih.gov/38276675/
The COVID-19 pandemic led to the rapid and worldwide development of highly effective vaccines against SARS-CoV-2. Although host genetic factors are known to affect vaccine efficacy for such respiratory pathogens as influenza and tuberculosis, the impact of host genetic variation on vaccine efficacy against COVID-19 is not well understood. Investigators used the diversity outbred mouse model to study the effects of genetic variation on vaccine efficiency. Data indicate that variations in vaccine response in mice are heritable, similar to that in human populations. Supported by ORIP (U42OD010924), NIAID, and NIGMS.
The Landscape of SETBP1 Gene Expression and Transcription Factor Activity Across Human Tissues
Whitlock et al., PLOS One. 2024.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0296328
The SET binding protein 1 (SETBP1) gene encodes a transcription factor (TF) involved in various cellular processes. Variants in SETBP1 can result in different diseases determined by the introduction (i.e., germline vs. somatic) and location of the variant. To better understand the tissue-specific mechanisms involving SETBP1, investigators analyzed publicly available RNA-sequencing data from the Genotype-Tissue Expression project. This study provides insight into the landscape of SETBP1 expression across 31 non-diseased human tissues and reveals tissue-specific expression and activity of SETBP1 and its targets. Supported by ORIP (U54OD030167) and NIGMS.
Plasticity of Intragraft Alloreactive T Cell Clones in Human Gut Correlates With Transplant Outcomes
Fu et al., Journal of Experimental Medicine. 2024.
https://pubmed.ncbi.nlm.nih.gov/38091025/
This study provides novel insights into tissue-resident memory T-cell (TRM) biology. The authors performed single-cell immune profiling to integrate clonotype, alloreactivity, and gene expression profiles of graft-repopulating recipient T cells in the intestinal mucosa after transplantation. They found that preexisting host-versus-graft (HvG)–reactive T cells were heterogenous and identified a trajectory from TRM to effector T/TRM profiles for rejection and dominant TRM profiles with tolerance in the quiescent allografts. Putative de novo HvG-reactive T cells showed a transcriptional profile skewed to cytotoxic effectors in rejecting grafts. Analysis of the inferred protein regulon network revealed upstream regulons for alloreactive T-cell tolerance and effector functions, opening opportunities for future translational studies to induce immune tolerance and overcome rejection. Supported by ORIP (S10OD020056) and NIAID.
Long-Acting Lenacapavir Protects Macaques Against Intravenous Challenge with Simian-Tropic HIV
Swanstrom et al., EBioMedicine. 2023.
https://pubmed.ncbi.nlm.nih.gov/37625266
Lenacapavir is a U.S. Food and Drug Administration–approved drug for treating multidrug-resistant HIV and needs to be taken only twice a year. Preexposure prophylaxis (PrEP) is a form of medicine that protects a person from getting sick rather than having to treat them after they get a disease. Because lenacapavir shows long-acting drug activity, it may be an ideal candidate for PrEP, as current PrEP medications require daily dosing. Researchers used experiments in vitro (in the lab, outside of a living organism) to show that lenacapavir has strong antiviral activity. Using 4- to 9-year-old male nonhuman primates (NHPs), researchers showed that a single dose of lenacapavir injected beneath the skin protected the NHPs from simian-tropic HIV-1 virus. After 419 days, researchers depleted T cell (a type of immune cell) levels in the NHPs and showed that low-level viral infections did not emerge. This study supports the evidence for moving lenacapavir into human PrEP development. Supported by ORIP (U42OD011123, P40OD028116), NCI, and NIAID.
Development and Validation of an Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Quantifying Lenacapavir Plasma Concentrations: Application to Therapeutic Monitoring
West III et al., Journal of Chromatography B. 2023.
https://pubmed.ncbi.nlm.nih.gov/37866010
Antiretroviral therapy (ART) is used to treat patients with HIV. Lenacapavir is a U.S. Food and Drug Administration–approved ART. Following initial doses of lenacapavir taken orally and injected beneath the skin, the patient gives themselves a dose by injection once every 6 months. With this long-acting and infrequent dosing, patients may need to be monitored to ensure that proper drug levels are achieved in the body to prevent viral mutations that could cause drug resistance. Researchers developed a novel mass spectrometry (a tool to measure molecules in a sample) method to test the effectiveness of ART by measuring lenacapavir levels in human plasma. The researchers validated the new method using a large range of clinically relevant doses. The results showed that the method is precise and consistent. This suggests that the method can monitor lenacapavir levels in human plasma and evaluate ART effectiveness in clinical settings. Supported by ORIP (S10OD028540) and NIAID.